Left Ventricular Assist Device as Bridge to Recovery for Anthracycline-Induced Terminal Heart Failure

Congestive Heart Failure

Volumn 18, Issue 5, 2012, Pages 291-294

  Appel, Jon M ^a   Sander, Kåre ^a   Hansen, Peter B ^a   Møller, Jacob E ^a   Krarup Hansen, Anders ^a   Gustafsson, Finn ^a  

^a Rigshopitalet ^*  (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CANDESARTAN; CEFUROXIME; DACTINOMYCIN; DIGOXIN; DOBUTAMINE; DOXORUBICIN; ETOPOSIDE; FUROSEMIDE; IFOSFAMIDE; METOPROLOL; MILRINONE; RAMIPRIL; SPIRONOLACTONE; UBIDECARENONE; VINCRISTINE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CARDIOGENIC SHOCK; CASE REPORT; CONSOLIDATION CHEMOTHERAPY; DEFIBRILLATOR; DEVICE INFECTION; DISEASE SEVERITY; DYSPNEA; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; FUNCTIONAL STATUS; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BIOPSY; HEART OUTPUT; HEMODYNAMIC MONITORING; HISTOLOGY; HOSPITAL DISCHARGE; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; MITRAL VALVE REGURGITATION; MULTIPLE CYCLE TREATMENT; PATIENT REFERRAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SIDE EFFECT; THORAX PAIN; TRICUSPID VALVE REGURGITATION;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOTOXINS; HEART FAILURE; HEART TRANSPLANTATION; HEART VENTRICLES; HEART-ASSIST DEVICES; HUMANS; MALE; YOUNG ADULT;

EID: 84866543580     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2012.00291.x     Document Type: Article

References (23)

1. Van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;CD005006.
2. Xu MF, Tang PL, Qian ZM, Ashraf M. Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci. 2001;68:889-901.
3. Zhou S, Starkov A, Froberg MK, et al. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61:771-777.
4. Kapelko VI, Williams CP, Gutstein DE, Morgan JP. Abnormal myocardial calcium handling in the early stage of adriamycin cardiomyopathy. Arch Physiol Biochem. 1996;104:185-191.
5. Zunino F, Capranico G. DNA topoisomerase II as the primary target of anti-tumor anthracyclines. Anticancer Drug Des. 1990;5:307-317.
6. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986;46:3722-3727.
7. Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep. 1978;62:865-872.
8. Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100:1058-1067.
9. Ryberg M, Nielsen D, Osterlind K, et al. Prognostic factors and long-term survival in 585 patients with metastatic breast cancer treated with epirubicin-based chemotherapy. Ann Oncol. 2001;12:81-87.
10. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710-717.
11. Chen B, Peng X, Pentassuglia L, et al. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7:114-121.
12. Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118:31-36.
13. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet. 1996;347:297-299.
14. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213-220.
15. Haj-Yahia S, Birks EJ, Dreyfus G, Khaghani A. Limited surgical approach for explanting the HeartMate II left ventricular assist device after myocardial recovery. J Thorac Cardiovasc Surg. 2008;135:453-454.
16. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47-58.
17. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355:1873-1884.
18. Freilich M, Stub D, Esmore D, et al. Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device. J Heart Lung Transplant. 2009;28:101-103.
19. Castells E, Roca J, Miralles A, et al. Recovery of ventricular function with a left ventricular axial pump in a patient with end-stage toxic cardiomyopathy not a candidate for heart transplantation: first experience in Spain. Transplant Proc. 2009;41:2237-2239.
20. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699-709.
21. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:820-828.
22. Sieswerda E, Van Dalen EC, Postma A, et al. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. 2011;9:CD008011.
23. Van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2011;0CD003917.